The FDA and Big Pharma: Watchdog or Lapdog?


Yesterday I wrote about the latest Big Pharma scandal to crawl out from under a rock. It shows, once again, the extent to which many doctors—in this case, psychiatrists—are compromised by their relationships with the drug companies, and the damage these conflicts of interest can do to patients. The same is true of the Food and Drug Administration—and in a way, that’s even worse, since the FDA is supposed to be our watchdog, and has instead too often become Big Pharma’s lapdog.

In an op-ed in yesterday’s Boston Globe, Marcia Angell offers a seven-point agenda to “restore the FDA to its purpose, which is to protect the public from unsafe food, drugs, and devices, not to accommodate the industries it regulates.” She sees the appointment of industry critic Joshua Sharfstein as deputy FDA commissioner as a promising sign—but only a beginning.

Angell, who teaches social medicine at Harvard Medical School and wrote a sharp book on how Big Pharma operates, suggests a series of changes to the system under which drugs are developed, approved, and marketed. Personally, I’d like to see something slightly more dramatic—maybe along the lines of replacing the lab animals used to test new drugs with pharmaceutical company executives. But as a realistic starting place for public policymaking in this area, Angell’s agenda is as sound as anything I’ve seen. 

Fact:

Mother Jones was founded as a nonprofit in 1976 because we knew corporations and the wealthy wouldn’t fund the type of hard-hitting journalism we set out to do.

Today, reader support makes up about two-thirds of our budget, allows us to dig deep on stories that matter, and lets us keep our reporting free for everyone. If you value what you get from Mother Jones, please join us with a tax-deductible donation so we can keep on doing the type of journalism that 2018 demands.

Donate Now
  • James Ridgeway is a former senior correspondent at Mother Jones and a 2012 Soros Justice Media Fellow. For more of his stories, click here.